The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. Until today this year the stock’s price performance recorded a decrease of -22.00%. However, over the last six months, the performance has been stronger by -60.46%. The price of NTLA decreased -11.87% over the last 30 days. And in the last five days, it has fallen by -15.08%.
Intellia Therapeutics Inc saw a rather unpredictable run in, in terms of market performance. The company’s stock reached its highest point at $33.28 on 03/05/24, while the lowest price for the same duration was marked at $8.96 on 03/04/25.
52-week price history of NTLA Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Intellia Therapeutics Inc’s current trading price is -72.67% away from its 52-week high, while its distance from the 52-week low is 1.51%. The stock’s price range during this period has varied between$8.96 and $33.28. The Intellia Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 5.94 million for the day, a figure considerably higher than their average daily volume of 2.98 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Intellia Therapeutics Inc (NTLA) has experienced a quarterly decline of -40.20% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 941.49M and boasts a workforce of 403 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 13.42, with a change in price of -8.74. Similarly, Intellia Therapeutics Inc recorded 2,953,700 in trading volume during the last 100 days, posting a change of -48.99%.
NTLA’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for NTLA stands at 0.24. Similarly, the long-term debt-to-equity ratio is also 0.22.
NTLA Stock Stochastic Average
Intellia Therapeutics Inc’s raw stochastic average for the past 50 days is presently 15.87%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 17.62%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 19.79% and 30.62%, respectively.
